Ifosfamide and cisplatin as neoadjuvant chemotherapy for advanced cervical carcinoma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 19, Issue 2, 1996, Pages 132-135

  Leone, B ^a,b   Vallejo, C ^a   Perez, J ^a   Cuevas, M A ^a   Machiavelli, M ^a   Lacava, J ^a   Focaccia, G ^a   Ferreyra, R ^a   Suttora, G ^a   Romero, A ^a   Castaldi, J ^a   Arroyo, A ^a   Rabinovich, M ^a  

^a Grupo Oncologico Cooperativo del Sur   (Argentina)

^b GOCS Neuquén ^*  (Argentina)

Author keywords

Cervical cancer; Cisplatin; Ifosfamide; Neoadjuvant chemotherapy

Indexed keywords

CISPLATIN; IFOSFAMIDE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; CISPLATIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; IFOSFAMIDE; MESNA; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; RADIOTHERAPY, ADJUVANT; REMISSION INDUCTION; SURVIVAL RATE; UTERINE CERVICAL NEOPLASMS;

EID: 9244241996     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199604000-00008     Document Type: Article

References (19)

1. Perez CA, Camel HM, Kuske RR, et al. Radiation therapy alone in the treatment of carcinoma of the uterine cervix: a 20-year experience. Gynecol Oncol 1986;23:127-40.
2. Jones WB. New approaches to high-risk cervical cancer. Advanced cervical cancer. Cancer 1993;71:1451-9.
3. Goldin A. Ifosfamide in experimental tumour systems. Semin Oncol 1982;9:14-23.
4. Buxton EJ, Meanwell CA, Mould JJ, et al. Phase II studies of bleomycin, ifosfamide and cisplatinum in cervix cancer. Acta Oncol 1988;27:545-9.
5. Buxton EJ, Meanwell CA, Hilton C, et al. Combination bleomycin, ifosfamide and cisplatin chemotherapy in cervix cancer. J Natl Cancer Inst 1989;81:359-61.
6. Lara PC, Garcia-Puche JL, Pedraza V. Cisplatin-ifosfamide as neoadjuvant chemotherapy in stage IIIB cervical uterine squamous-cell carcinoma. Cancer Chemother Pharmacol 1990;26: 36-8.
7. Tobias J, Buxton J, Blackledge G, et al. Neoadjuvant bleomycin, ifosfamide and cisplatin in cervical cancer. Cancer Chemother Pharmacol 1990;26:59-62.
8. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981;47:207-14.
9. Piver MS, Rutledge F, Smith JP. Five classes of extended hysterectomy for women with cervical cancer. Obstet Gynecol 1974;44:265.
10. Perry MC. Appendix. WHO toxicity guidelines. In: Perry MC, ed. The chemotherapy source book. Baltimore: 1992:1132-44.
11. Kaplan EC, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:437-81.
12. Simes RJ, Zelen M. Exploratory data analysis and the use of the hazard function for interpreting survival data: an investigator's primer. J Clin Oncol 1985;3:1418-31.
13. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984;2: 1281-8.
14. Thigpen T, Vance R, Lambuth B, et al. Chemotherapy for advanced or recurrent gynecologic cancer. Cancer 1987;60:2104-16.
15. Alberts DS, Garcia D, Mason-Liddil N. Cisplatin in advanced cancer of the cervix: an update. Semin Oncol 1991;18:11-24.
16. Trimble EL, Ungerleider RS, Abrams JA, et al. Neoadjuvant therapy in cancer treatment. Cancer 1993;72:3515-24.
17. Sohuami L, Gil RA, Allan SE, et al. A randomized trial of chemotherapy followed by pelvic radiation therapy in stage IIIB carcinoma of the cervix. J Clin Oncol 1991;9:970-7.
18. Chauvegne J, Rohart J, Heron JF, et al. Randomized trial of initial chemotherapy in 151 locally advanced carcinoma of the cervix (T2B-N1, MO). Bull Cancer 1990;77:1007-24.
19. Braly PS, Klevecz RR. Flow cytometry evaluation of ovarian cancer. Cancer 1993;71:1621-8.